- Cat. No.
- A18703
BA-53038B
BA-53038B is a HBV core protein allosteric modulator (CpAM), binding to the HAP pocket and modulating HBV capsid assembly in a distinct manner, with an EC50 value of 3.32 μM.
Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Hepatitis B virus (HBV) research compounds act on viral replication and on host steps of infection. HBV is a small enveloped DNA virus that copies its genome by reverse transcription of a pregenomic RNA inside the viral nucleocapsid. Nucleoside analogs such as telbivudine are phosphorylated in cells and then interfere with this reverse transcription step. Capsid assembly modulators work elsewhere in the cycle, and heteroaryldihydropyrimidines of the BAY41-4109 racemic type were shown to deplete nucleocapsids, while morphothiadin is a later capsid-directed compound. Virus entry depends on the bile acid transporter sodium taurocholate cotransporting polypeptide (NTCP), identified as the receptor for HBV. Catalpol is an iridoid glycoside listed here for reported activity in HBV cell models.
BA-53038B is a HBV core protein allosteric modulator (CpAM), binding to the HAP pocket and modulating HBV capsid assembly in a distinct manner, with an EC50 value of 3.32 μM.
GLP-26 is a HBV capsid assembly modulators (CAM), inhibits HBV DNA replication in Hep AD38 system (IC50=3 nM), and reduces cccDNA by >90% at 1 μM. GLP-26 disrupts the encapsidation of pre-genomic RNA, causes nucleocapsid disassembly and reduces cccDNA pools.
RIG-1 modulator 1 is an anti-viral compound which can be useful for the treatment of viral infections including influenza virus, HBV, HCV and HIV extracted from patent WO 2015172099 A1.
JNJ-632 is a hepatitis B virus (HBV) capsid assembly modulator (CAM).
Synonyms: JNJ-6379; JNJ-56136379
Bersacapavir is an HBV capsid assembly modulator that targets hepatitis B virus (HBV) replication. It exhibits a dual mechanism of action by forming complete genome-free empty capsids and inhibiting the de novo synthesis of covalently closed circular DNA (cccDNA). This compound is valuable for research applications focusing on HBV infection and the development of antiviral therapies.
NVR 3-778 is an oral bioavailable capsid assembly modulator (CAM) targeting hepatitis B virus (HBV). As a member of the sulfamoylbenzamide (SBA) class, it exhibits significant anti-HBV activity. This compound is suitable for research applications focused on investigating HBV replication and the mechanisms of viral assembly, thereby contributing to the development of therapeutic strategies against HBV infection.
ALG-001075 functions as a capsid assembly modulator (CAM) and serves as an orally active inhibitor of hepatitis B virus (HBV). This compound effectively inhibits HBV DNA production, along with extracellular HBsAg/HBeAg and intracellular HBV RNA in primary human hepatocytes. In the AAV-HBV mouse model, ALG-001075 demonstrates significant reductions in circulating HBV DNA. It is valuable for research applications focused on chronic hepatitis B (CHB).
VNRX-9945 is a potent capsid assembly modulator targeting Hepatitis B Virus (HBV) with an EC50 of 2.6 nM. It exhibits broad antiviral activity against multiple HBV genotypes in vitro, demonstrating its effectiveness in diverse biological contexts. Additionally, VNRX-9945 shows favorable pharmacokinetic properties across various species and has demonstrated significant antiviral efficacy in adeno-associated virus mouse models of HBV infection, making it a valuable tool for HBV research and therapeutic development.
SHR5133 is a potent HBV capsid assembly modulator that functions through the inhibition of hepatitis B virus (HBV) capsid assembly. Demonstrating an EC50 of 26.6 nM, SHR5133 effectively reduces HBV DNA levels. This compound is primarily utilized in research applications focused on HBV infection and therapeutic development.
HBV-IN-17 is a potent modulator of Hepatitis B Virus (HBV) capsid assembly, exhibiting an effective concentration (EC50) of 511 nM. This compound targets the viral capsid formation, disrupting the assembly process critical for HBV replication. It is useful in research applications focused on understanding HBV biology and developing potential therapeutics for HBV infection.
BA38017 is a potent modulator of HBV core protein assembly, specifically targeting the hepatitis B virus (HBV) replication process. It demonstrates significant inhibitory activity with an EC50 of 0.20 μM, making it a valuable tool for studying HBV biology. This compound is essential for research applications focused on understanding HBV pathogenesis and evaluating potential therapeutic strategies against hepatitis B infection.
HBV-IN-18 is an HBV capsid assembly modulator (CpAM) that selectively targets the Hepatitis B virus capsid. It demonstrates a biological activity with an EC50 value of 2790 nM, indicating its potential in inhibiting viral assembly. This compound is applicable in research focused on understanding Hepatitis B virus biology and developing antiviral therapies.
Out of stock
All 3 sizes
CAB7-3 is an orally active capsid assembly modulator targeting Hepatitis B Virus (HBV), exhibiting potent antiviral activity. It demonstrates significant efficacy with EC50 values of 70 nM in HepDES19 cells, 1 nM in HepAD38 cells, and 2 nM in HBV-infected HLCZ01 cells. CAB7-3 effectively reduces hepatic HBV core protein levels and suppresses viral replication in vivo. This compound is valuable for research aimed at understanding and treating HBV infections.
Out of stock
All 3 sizes